Actualités et Activités de CStone Pharmaceuticals
Dirigeants
Voir l'organigramme avec ses 3 principaux dirigeants
Biographies les plus recherchées chez CStone Pharmaceuticals
- Jason Yang, Chief Executive Officer
- Yip Betty Ho, Independent Non-Executive Director
- Michael Choi, Chief Business and Strategy Officer
Changements de dirigeants chez CStone Pharmaceuticals
- Yip Betty Ho, a rejoint l'entreprise comme Independent Non-Executive Director (publié le 2 janvier 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez CStone Pharmaceuticals.
Pharmacie
CStone Pharmaceuticals a 1 833 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par CStone Pharmaceuticals
- CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody-CStone Pharmaceuticals
- CStone Announces First Patient Enrolled in the Global Multicenter Phase 1b Clinical Trial of CS5001 (ROR1 ADC)-CStone Pharmaceuticals
- Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting-CStone Pharmaceuticals
- CStone and Pharmalink Enter into Strategic Partnership for Sugemalimab in Middle East and North Africa Region and South Africa-CStone Pharmaceuticals
- CStone's CMO Dr. Qingmei Shi Attends World Companion Diagnostics & Liquid Biopsy Summit APAC, Shares Insights on Precision Medicine and Companion Diagnostics Co-development-CStone Pharmaceuticals
- CStone Presents Preclinical Data on CS2009 at the 2024 SITC Annual Meeting-CStone Pharmaceuticals
- CStone to Present Latest Clinical Data on CS5001 for Lymphoma at the 66th ASH Annual Meeting-CStone Pharmaceuticals
- CStone Announces Publication of Population Pharmacokinetics Modelling of Sugemalimab in British Journal of Clinical Pharmacology-CStone Pharmaceuticals
- CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK-CStone Pharmaceuticals
- CStone to Present Preclinical Data on CS2009 at the 2024 SITC Annual Meeting-CStone Pharmaceuticals
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de CStone Pharmaceuticals
- CStone Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- CStone Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
